Daya CNS is a company headquartered in the United States.
Daya CNS develops novel non-opioid pyridoindole small molecule medications targeting chronic pain, neuropathies, arthritis, substance abuse disorders, and neuropsychiatric conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.